Eltrombopag
A Phase II Study of Eltrombopag as a Novel Therapeutic Approach for Patients With Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) With TET2 Mutations
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 25 patients (estimated)
- Sponsors
- Case Comprehensive Cancer Center
- Tags
- Thrombopoietin Receptor Agonist (TPO-RA), White Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2016
- NCT Identifier
- NCT06630221
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.